Less mammographic density after nasal versus oral administration of postmenopausal hormone therapy

References

• McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. Am J Roentgenol 1994;163:311–15
   PubMed Web of Science ®Google Scholar
• Kenemans P, Genazzani AR, Palacios S, Schneider HP. Pulsed estrogen exposure selectively modulates tissue response: a hypothesis. Gynecol Endocrinol 2004;18:159–64
   PubMed Web of Science ®Google Scholar
• Eilertsen AL, Karssemeijer N, Skaane P, Qvigstad E, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. BJOG 2008;115:773–9
   PubMed Web of Science ®Google Scholar
• Boyd NF, Guo H, Martin LJ, . Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356: 227–36
   PubMed Web of Science ®Google Scholar
• van Gils CH, Otten JD, Verbeek AL, Hendriks JH, Holland R. Effect of mammographic breast density on breast cancer screening performance: a study in Nijmegen, The Netherlands. J Epidemiol Commun Health 1998;52:267–71
   PubMed Web of Science ®Google Scholar
• Saftlas AF, Wolfe JN, Hoover RN, . Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol 1989;129:518–26
   PubMed Web of Science ®Google Scholar
• Vachon CM, van Gils CH, Sellers TA, . Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res 2007;9:217
   PubMed Web of Science ®Google Scholar
• Karssemeijer N. Automated classification of parenchymal patterns in mammograms. Phys Med Biol 1998;43:365–78
   PubMed Web of Science ®Google Scholar
• Kerlikowske K, Ichikawa L, Miglioretti DL, . Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386–95
   PubMed Web of Science ®Google Scholar
• Hemelaar M, Kenemans P, de BL, van de Weijer PH, van der Mooren MJ. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. Fertil Steril 2006;85:979–88
   PubMed Web of Science ®Google Scholar
• Hemelaar M, Kenemans P, Schalkwijk CG, Braat DD, van der Mooren MJ. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. Hum Reprod 2006;21:1635–42
   PubMed Web of Science ®Google Scholar
• Hemelaar M, Rosing J, Kenemans P, Thomassen MC, Braat DD, van der Mooren MJ. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 2006;26:1660–6
   PubMed Web of Science ®Google Scholar
• Hemelaar M, Kenemans P, Hack CE, Klipping C, van der Mooren MJ. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. Menopause 2008;15:248–55
   PubMed Web of Science ®Google Scholar
• Verhoeven MO, Hemelaar M, Teerlink T, Kenemans P, van der Mooren MJ. Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study. Atherosclerosis 2007;195:181–8
   PubMed Web of Science ®Google Scholar
• Castelo-Branco C, Palacios S, Vazquez F, . Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. Fertil Steril 2007;88:383–9
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Pornel B, Koninckx PR, Palacios S, Christiansen C. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen. Hum Reprod 2009;24:1739–47
   PubMed Web of Science ®Google Scholar
• Wolfe JN, Saftlas AF, Salane M. Mammographic parenchymal patterns and quantitative evaluation of mammographic densities: a case-control study. Am J Roentgenol 1987;148:1087–92
   PubMed Web of Science ®Google Scholar
• Byrne C, Schairer C, Wolfe J, . Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995;87:1622–9
   PubMed Web of Science ®Google Scholar
• Cohen J. A coefficient of agreement for nominal scales. Educational Psychological Measurement 1960;20:37–46
   Web of Science ®Google Scholar
• Sackett DL, Haynes RB, Tugwell P. Clinical Epidemiology: a Basis for Clinical Medicine. Boston: Little, Brown and Company, 1985
   Google Scholar
• Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968;70:213–20
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Kuller LH, Prentice RL, . Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573–87
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28
   PubMed Web of Science ®Google Scholar
• Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence. Breast Cancer Res 2008;10:201
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N, . The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670–4
   PubMed Web of Science ®Google Scholar
• Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 2000;11:653–62
   PubMed Web of Science ®Google Scholar
• Bremnes Y, Ursin G, Bjurstam N, Lund E, Gram IT. Different types of postmenopausal hormone therapy and mammographic density in Norwegian women. Int J Cancer 2007;120:880–4
   PubMed Web of Science ®Google Scholar
• Pettersen PC, Raundahl J, Loog M, Nielsen M, Tanko LB, Christiansen C. Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms. Climacteric 2008;11: 135–43
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Hendrix SL, Langer RD, . Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243–53
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, . Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Haars G, van Noord PA, van Gils CH, Grobbee DE, Peeters PH. Measurements of breast density: no ratio for a ratio. Cancer Epidemiol Biomarkers Prev 2005;14:2634–40
   PubMed Web of Science ®Google Scholar